Decheng Capital
$732M 13F equity value
15 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Decheng Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| CGON | CG ONCOLOGY INC | 6,371,669 | $453M | 61.9% |
| NUVB | Nuvation Bio Inc. | 25,954,439 | $147M | 20.1% |
| AARD | AARDVARK THERAPEUTICS INC | 3,917,299 | $23M | 3.1% |
| ACRS | Aclaris Therapeutics, Inc. | 4,041,736 | $21M | 2.9% |
| UPB | Upstream Bio Inc. | 2,724,868 | $19M | 2.6% |
| RCUS | Arcus Biosciences, Inc | 464,779 | $14M | 2.0% |
| EQ | Equillium Inc. | 4,447,308 | $14M | 1.9% |
| RVMD | REVOLUTION MEDICINES INC(NSM) | 52,667 | $10M | 1.3% |
| LYEL | Lyell Immunopharma, Inc. | 692,050 | $10M | 1.3% |
| BYSI | BeyondSpring Inc. | 3,800,702 | $7M | 0.9% |
Track Decheng Capital's 13F portfolio: $732M in reported holdings, 15 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}